Please login to the form below

Not currently logged in

VC firm expands team, appoints Genzyme and Lilly veterans

New roles for James Geraghty, Steven Paul, Daniel Lynch and John Maraganore

Third Rock Steven PaulUS venture capital company Third Rock Ventures has expanded its team by appointing a number of industry heavyweights.

The firm, which focuses on building healthcare companies, has appointed former executives from Genzyme, Lilly, ImClone and Alnylam to help it translate scientific innovation into new companies.

James Geraghty, who has spent 20-years at Genzyme, becomes entrepreneur-in-residence, while the former president of Lilly Research Laboratories, Steven Paul (pictured right), takes on an increased role at Third Rock with a position as a venture partner.

Third Rock Daniel LynchAlso joining Third Rock as venture partners are Daniel Lynch (pictured right), a former CEO of ImClone Systems, and Alnylam's CEO John Maraganore. 

Robert Tepper, partner at Third Rock Ventures, said: “These leaders have demonstrated - through decades of experience - their ability to integrate science and business.

“The depth of their expertise across commercial, business development, R&D, drug discovery and product development will be invaluable to Third Rock as we focus on translating scientific innovation into exceptional companies that make a difference for patients.”

15th May 2013

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...